Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for patients that don't have insurance.

Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...

On February 21, 2025, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order determining that the semaglutide ...

Health experts have slammed the FDA as 'corrupt' and 'in bed with Big Pharma' after its former drug chief Dr Patrizia ...

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.

Key Takeaways Eli Lilly lowered the price of two dosage levels of its weight-loss drug Zepbound for patients paying out of ...

The industry wants the ability to make bolder health claims and to get the government and private insurers to pay for its products — as they do FDA-approved drugs.

Ozempic side effects that are more common in females vs. males include nausea, vomiting, dizziness, and headache. Females ...

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

Control-IQ+ automated insulin delivery technology from Tandem Diabetes Care cleared by FDA for people with type 2 diabetes.

Drug compounders sued the U.S. Food and Drug Administration on Monday over its decision last week to remove Novo Nordisk's ...

The US Food and Drug Administration’s new standards for foods before they can be labeled as “healthy” on their packaging will ...